Chugai Filed Tecentriq for 1st Line Lung Cancer in March as Players Race to Grab Low PD-L1 Expressers

Chugai Pharmaceutical filed its anti-PD-L1 antibody Tecentriq (atezolizumab) for the first-line treatment of non-small cell lung cancer (NSCLC) in March as I/O drug makers race to win patients with low PD-L1 expressions in the frontline setting. In Japan, Tecentriq was...read more